5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Arfe, A.; Barnett, E.; Cohn, E. D.; Zhao, J.; Carbone, E.; Zanone, M.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314
    Meeting Abstract

    Iyer, G.; Tangen, C.; Sarfaty, M.; Regazzi, A. M.; Lee, I. L. C.; Choi, W.; Dinney, C. P. N.; Flaig, T. W.; Thompson, I. M.; McConkey, D. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscleinvasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)
    Meeting Abstract

    Iyer, G.; Ballman, K. V.; Atherton, P. J.; Murray, K.; Kwok, Y.; Steen, P. D.; Baghaie, S.; Rosenberg, J. E.; Morris, M. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance)
    Meeting Abstract

    Iyer, G.; Halabi, S.; Luo, B.; Rosenberg, J. E.; Choi, W.; Al-Ahmadie, H. A.; Mountain, J.; Regazzi, A. M.; Fong, M.; Mouw, K. W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Estimating clear cell renal cell carcinoma transcriptomic signatures using machine learning and histopathology images
    Meeting Abstract

    Hassanpour, S.; Tomita, N.; Kotecha, R.; Lee, C. H.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The frequency of second primary malignancies and colonic polyps in Lynch syndrome with MSI tumors following immune checkpoint blockade
    Meeting Abstract

    Harrold, E.; Patel, Z.; Maio, A.; Cercek, A.; Yaeger, R.; Segal, N. H.; Reidy, D. L.; O'Reilly, E. M.; Desai, A. M.; Carlo, M. I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial
    Meeting Abstract

    Harding, J. J.; Piha-Paul, S. A.; Shah, R. H.; Cleary, J. M.; Quinn, D. I.; Brana, I.; Moreno, V.; Borad, M. J.; Loi, S.; Spanggaard, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Gupta, S.; Bellmunt, J.; Plimack, E. R.; Sonpavde, G. P.; Grivas, P.; Apolo, A. B.; Pal, S. K.; Siefker-Radtke, A. O.; Flaig, T. W.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)
    Meeting Abstract

    Gupta, S.; Ballman, K. V.; Galsky, M. D.; Morris, M. J.; Chen, R. C.; Chan, T. A.; Dercle, L.; Wen, Y.; Sridhar, S. S.; Yen, A. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Meeting Abstract

    Halabi, S.; Roy, A.; Rydzewska, L.; Godolphin, P.; Parmar, M. K. B.; Hussain, M. H. A.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save